CD19 and neoplasm: In xenograft models of aggressive B-cell lymphoma, the coinjection of this stabilized version of IL-15 together with CD19-specific CAR-T cells augmented CAR-T-cell performance eventuating in the longer survival of tumor-bearing mice [49].